The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a ...

Amgen recently had two big wins. First, after years of wrangling with the FDA, they finally won approval for their innovative osteoporosis drug, Evenity. Second, Amgen launched Evenity at a price ...

THOUSAND OAKS, Calif. and BRUSSELS, April 1, 2017/ PRNewswire/-- Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of ...

The U.S. Food and Drug Administration has approved a drug treatment specifically for postmenopausal women with a high risk of breaking bones. Doses are taken in two back-to-back injections ...

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab) to ...

EVENITY has been studied for its potential to reduce the risk of fractures in an extensive global Phase 3 program that included two large fracture trials comparing EVENITY to either placebo or active ...

The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history ...

FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files By Deena Beasley (Reuters) - Amgen Inc ...

DEAR DR. ROACH: I’ve been taking calcium supplements for many years to assist in strengthening my bones. I’m 74, weigh less than 95 pounds and stand 5 feet tall. I’m on the verge of osteoporosis, and ...

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures. The FDA announced Tuesday that the drug, called ...